Structural Insight into the Resistance of the SARS-CoV-2 Omicron BA.4 and BA.5 Variants to Cilgavimab

Structural Insight into the Resistance of the SARS-CoV-2 Omicron BA.4 and BA.5 Variants to Cilgavimab

We have recently revealed that the new SARS-CoV-2 Omicron sublineages BA.4 and BA.5 exhibit increased resistance to cilgavimab, a therapeutic monoclonal antibody, and the resistance to cilgavimab is attributed to the spike L452R substitution. However, it remains unclear how the spike L452R substitut...

Full description

Bibliographic Details
Main Authors: Shigeru Fujita, Yusuke Kosugi, Izumi Kimura, Daichi Yamasoba, The Genotype to Phenotype Japan (G2P-Japan) Consortium, Kei Sato
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Viruses
Subjects:
SARS-CoV-2
COVID-19
Omicron
BA.4
BA.5
cilgavimab
Online Access:https://www.mdpi.com/1999-4915/14/12/2677

Internet

https://www.mdpi.com/1999-4915/14/12/2677

Similar Items